Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Sacituzumab Tirumotecan versus Non-platinum Chemotherapy in Pretreated Advanced Urothelial Carcinoma
jRCT2051260020Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Started May 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2051260020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260020.